Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
NCT ID: NCT02867709
Last Updated: 2019-03-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1686 participants
INTERVENTIONAL
2016-08-26
2018-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02828020
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
NCT02873221
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
NCT04492020
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
NCT05264129
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ubrogepant 25 mg
1 ubrogepant 25 milligram (mg) tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
Ubrogepant
Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching Ubrogepant
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Ubrogepant 50 mg
1 ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
Ubrogepant
Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching Ubrogepant
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo
1 placebo-matching ubrogepant tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
Placebo-matching Ubrogepant
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ubrogepant
Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching Ubrogepant
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Migraine onset before age 50
* History of migraines typically lasting between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
* History of 2 to 8 migraine attacks per month with moderate to severe headache pain in each of the previous 3 months.
Exclusion Criteria
* Has taken medication for acute treatment of headache (including acetaminophen, nonsteroidal anti-inflammatory drugs \[NSAIDs\], triptans, ergotamine, opioids, or combination analgesics) on 10 or more days per month in the previous 3 months
* Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine
* Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
* Required hospital treatment of a migraine attack 3 or more times in the previous 6 months
* Has a chronic non-headache pain condition requiring daily pain medication
* Has a history of malignancy in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
* Has a history of any prior gastrointestinal conditions (eg, diarrhoea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of investigational product; participants with prior gastric bariatric interventions which have been reversed are not excluded
* Has a history of hepatitis within previous 6 months.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adele Thorpe
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Advantage, Inc./Simon Williamson Clinic
Birmingham, Alabama, United States
Clinical Research Advantage, Inc./East Valley Family Physicians, PLC
Chandler, Arizona, United States
St. Joseph's Hospital & Medical Center - Barrow Neurologic Institute (BNI)
Phoenix, Arizona, United States
Clinical Research Advantage, Inc./Central Phoenix Medical Clinic, LLC
Phoenix, Arizona, United States
Mayo Clinic Arizona, May Clinic Scottsdale
Scottsdale, Arizona, United States
Radiant Research Inc.
Tucson, Arizona, United States
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Axiom Research, LLC
Apple Valley, California, United States
Hope Clinical Research
Canoga Park, California, United States
Axiom Research, LLC
Colton, California, United States
Pharmacology Research Institute
Encino, California, United States
Neuro-Pain Medical Center
Fresno, California, United States
California Headache and Balance Center
Fresno, California, United States
Sun Valley Research Center
Imperial, California, United States
Grossmont Center For Clinical Research
La Mesa, California, United States
Pharmacology Research Institute
Los Alamitos, California, United States
California Advanced Neurotherapeutic, Inc.
Los Angeles, California, United States
Cedars Sinai Pain Center
Los Angeles, California, United States
Pharmacology Research Institute
Newport Beach, California, United States
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California, United States
Desert Valley Research
Rancho Mirage, California, United States
George J Rederich MD, Inc
Redondo Beach, California, United States
Artemis Institute For Clinical Research
San Diego, California, United States
Clinical Research Advantage, Inc./Cassidy Medical Group-Vista
Vista, California, United States
Clinicos, LLC
Colorado Springs, Colorado, United States
Colorado Neurological Institute
Englewood, Colorado, United States
Advanced Neurosciences Research, LLC
Fort Collins, Colorado, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Radiant Clinical Research
Washington D.C., District of Columbia, United States
Aventura Neurological Associates
Aventura, Florida, United States
Clinical Research South Florida
Coral Gables, Florida, United States
Avail Clinical Research, LLC
DeLand, Florida, United States
Broward Research Group
Hollywood, Florida, United States
Health Awareness, Inc.
Jupiter, Florida, United States
Neurology Associates, P.A.
Maitland, Florida, United States
LCC Medical Research Institute, LLC
Miami, Florida, United States
Well Pharma Medical Research, Corp.
Miami, Florida, United States
Panax Clinical Research
Miami Lakes, Florida, United States
Suncoast Clinical Research
New Port Richey, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Sensible Healthcare, LLC
Ocoee, Florida, United States
QPS MRA, LLC (Miami Research Associates)
South Miami, Florida, United States
Palm Beach Research Center
West Palm Beach, Florida, United States
The Kaufmann Clinic, Inc.
Atlanta, Georgia, United States
NeuroTrials Research, Inc.
Atlanta, Georgia, United States
Advanced Clinical Research
Meridian, Idaho, United States
Clinical Research Advantage, Inc./Michigan Avenue Internists
Chicago, Illinois, United States
Cedar Crosse Research Center
Chicago, Illinois, United States
Robbins Headache Clinic
Riverwoods, Illinois, United States
Josephson Wallack Munshower Neurology P.C.
Indianapolis, Indiana, United States
Norton Neurology Services MS Services
Louisville, Kentucky, United States
L-MARC Research Center
Louisville, Kentucky, United States
Seton Medical Group
Baltimore, Maryland, United States
Overlea Personal Physicians
Baltimore, Maryland, United States
BTC of New Bedford
New Bedford, Massachusetts, United States
Beacon Clinical Research, LLC
Quincy, Massachusetts, United States
New England Regional Headache Center, Inc.
Worcester, Massachusetts, United States
Quest Research Institute
Farmington Hills, Michigan, United States
Minneapolis Clinic of Neurology
Golden Valley, Minnesota, United States
The Headache Center
Ridgeland, Mississippi, United States
Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC
Fremont, Nebraska, United States
Clinical Research Advantage, Inc
Omaha, Nebraska, United States
Meridian Clinical Research, LLC
Omaha, Nebraska, United States
Hope Research Institute
Las Vegas, Nevada, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Princeton Medical Institute
Princeton, New Jersey, United States
Princeton Center for Clinical Research
Skillman, New Jersey, United States
Bio Behavioral Health
Toms River, New Jersey, United States
DENT Neurosciences Research Center
Amherst, New York, United States
Cushing Neuroscience Institute North Shore-LIJ Medical Group
Great Neck, New York, United States
ProHealth Care Associates, LLP
Plainview, New York, United States
Upstate Clinical Research Associates, LLC
Williamsville, New York, United States
Westchester Neuro. Const
Yonkers, New York, United States
Carolina Headache Institute
Durham, North Carolina, United States
Headache Wellness Center, PC
Greensboro, North Carolina, United States
Lake Shore Clinical Research, LLC
Mooresville, North Carolina, United States
Raleigh Neurology Associates, PA
Raleigh, North Carolina, United States
Plains Clinical Research Center, LLC
Fargo, North Dakota, United States
Radiant Research, Inc.
Akron, Ohio, United States
Sentral Clinical Research Services
Cincinnati, Ohio, United States
Patient Priority Clinical Sites, LLC
Cincinnati, Ohio, United States
University of Cincinnati Dept of Psychiatry & Behavioral Neuroscience
Cincinnati, Ohio, United States
CTI Clinical Research Center
Cincinnati, Ohio, United States
Rapid Medical Research, Inc.
Cleveland, Ohio, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Sooner Clinical Research
Oklahoma City, Oklahoma, United States
Preferred Primary Care Physicians, Inc.
Pittsburgh, Pennsylvania, United States
Preferred Primary Care Physicians
Uniontown, Pennsylvania, United States
Abington Neurological Associates, Ltd.
Willow Grove, Pennsylvania, United States
Radiant Research, Inc.
Anderson, South Carolina, United States
Clinical Trials of South Carolina
Charleston, South Carolina, United States
Vista Clinical Research
Columbia, South Carolina, United States
Hillcrest Clinical Research, LLC
Simpsonville, South Carolina, United States
Middle Tennessee Clinical Research
Fayetteville, Tennessee, United States
Volunteer Research Group
Knoxville, Tennessee, United States
Baptist Memorial Medical Group (Neurology Specialist - Headache Clinic)
Memphis, Tennessee, United States
Texas Neurology, P.A.
Dallas, Texas, United States
Radiant Research, Inc
Dallas, Texas, United States
Research Trials Worldwide, LLC
Humble, Texas, United States
Advanced Research Institute
Ogden, Utah, United States
Charlottesville Medical Research Center, LLC
Charlottesville, Virginia, United States
iNeuro Headache Specialist
McLean, Virginia, United States
Clinical Research Associates of Tidewater
Norfolk, Virginia, United States
Blue Ridge Research Center, LLC
Roanoke, Virginia, United States
Sentara Neurology Specialists
Virginia Beach, Virginia, United States
Summit Research Network Seattle, LLC
Seattle, Washington, United States
South Puget Sound Neurology
Tacoma, Washington, United States
West Virginia University, Department of Neurology
Morgantown, West Virginia, United States
Medical College of Wisconsin, Department of Neurology
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Goadsby PJ, Jurgens TP, Brand-Schieber E, Nagy K, Liu Y, Boinpally R, Stodtmann S, Trugman JM. Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials. Cephalalgia. 2025 Feb;45(2):3331024251320610. doi: 10.1177/03331024251320610.
Johnston KM, Powell L, Popoff E, Harris L, Croop R, Coric V, L'Italien G. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm. Clin J Pain. 2022 Nov 1;38(11):680-685. doi: 10.1097/AJP.0000000000001072.
Lipton RB, Singh RBH, Revicki DA, Zhao S, Shewale AR, Lateiner JE, Dodick DW. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain. 2022 Apr 25;23(1):50. doi: 10.1186/s10194-022-01419-7.
Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Adv Ther. 2022 Jan;39(1):692-705. doi: 10.1007/s12325-021-01923-3. Epub 2021 Dec 7.
Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia. 2021 Aug;41(9):979-990. doi: 10.1177/03331024211000311. Epub 2021 Apr 19.
Hutchinson S, Dodick DW, Treppendahl C, Bennett NL, Yu SY, Guo H, Trugman JM. Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials. Neurol Ther. 2021 Jun;10(1):235-249. doi: 10.1007/s40120-021-00234-7. Epub 2021 Feb 20.
Goadsby PJ, Blumenfeld AM, Lipton RB, Dodick DW, Kalidas K, M Adams A, Jakate A, Liu C, Szegedi A, Trugman JM. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. Cephalalgia. 2021 Apr;41(5):546-560. doi: 10.1177/0333102420970523. Epub 2020 Nov 26.
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019 Nov 19;322(19):1887-1898. doi: 10.1001/jama.2019.16711.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
More Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UBR-MD-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.